OssDsign
OssDsign's revenues for the fourth quarter of 2023 are expected to exceed market estimates
According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.
"The continued strong market performance of OssDsign Catalyst means we have already exceeded market expectations after only two months in the quarter and confirms the attractiveness of our recently announced strategy shift to fully focus on the high-margin orthobiologics franchise”, said Morten Henneveld, CEO of OssDsign.
A complete financial statement for the fourth quarter will be presented in the year-end report for 2023, to be published on February 6, 2024.
This disclosure contains information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-12-2023 08:00 CET.
| Datum | 2023-12-06, kl 08:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!